Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Cerus Corporation inks FDA contract for Pathogen Reduction technology. Twist Biosciences strikes new deal for T Cell therapies. Gossamer Bio announces disappointing data for Asthma and Chronic Rhinosinusitis trials. For further details see: Cerus Inks FDA Contract, And O...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will host a Twist Biopharma Analyst & Investor Event on Friday, October 23, 2020. The event is ...
Twist Bioscience (TWST) +3% in premarket, has entered into a partnership with Neogene Therapeutics for development of personalized chimeric antigen receptor ((CAR)) T cell therapies and T cell receptor ((TCR)) therapies for cancer.The companies will leverage Neogene’s pr...
Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high...
Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its CEO and co-founder, Emily M. Leproust, Ph.D., will receive the 2020 Rosalind Franklin Award for Leadership at the Bi...
Graphic Source: Twist Bioscience Corporation Introduction: What is Twist Biosciences? Twist Bioscience Corporation (TWST) is a high-growth synthetic biology company that launched a uniquely low-cost DNA synthesis platform in 2016 based on proprietary silicon chip DNA writing. This has si...
Insider buying decreased significantly last week with insiders purchasing $31.16 million of stock compared to $111.24 million in the week prior. Selling also decreased significantly with insiders selling $749.85 million of stock last week compared to $2.46 billion in the week prior. Sell/Bu...
Partnerships Twist Bioscience ( TWST ) has been doing well during the pandemic and the first 9 months of its 2020 fiscal as announced in its Q3 earnings call: At the beginning of the fiscal year, we outlined we'll secure between five and 10 partnerships, as Emily noted, and we ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, wi...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...